Ablynx is preparing to a US filing for its caplacizumab for the rare, life-threatening blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) following additional data from a ...

The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is also ...